v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 173,933 $ 143,537
Cost of revenue:    
Total cost of revenue 72,772 55,309
Gross profit 101,161 88,228
Operating expenses:    
Research, development and clinical trials 24,879 17,160
Selling, general and administrative 62,985 43,625
Total operating expenses 87,864 60,785
Income from operations 13,297 27,443
Other income (expense):    
Interest expense (7,170) (3,461)
Interest income and other income (expense), net 2,358 2,694
Total other expense, net (4,812) (767)
Income before income taxes 8,485 26,676
Provision for income taxes (1,170) (994)
Net income $ 7,315 $ 25,682
Net income per share, basic $ 0.21 $ 0.76
Net income per share, diluted $ 0.2 $ 0.7
Weighted average common shares outstanding, basic 34,384,207 33,721,603
Weighted average common shares outstanding, diluted 36,194,023 39,914,487
Net product revenue [Member]    
Revenue:    
Total revenue $ 107,972 $ 88,234
Cost of revenue:    
Total cost of revenue 24,308 16,312
Service Revenue [Member]    
Revenue:    
Total revenue 65,961 55,303
Cost of revenue:    
Total cost of revenue $ 48,464 $ 38,997